laboratory specialized in the treatment of rare neurological diseases

« A disruptive technology, which can be applied in the treatment of numerous conditions »

Information on the total number of voting rights and shares (french only)
Download PDF File (650 Ko)

End of stabilization period and implementation of a liquidity contract (french only)
Download PDF File (917 Ko)

Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris
Download PDF File (637 Ko)

Success of Theranexus' IPO on Euronext Growth in Paris
Download PDF File (917 Ko)

Theranexus announces issuance of US patent covering its drug candidate THN102 for treatment of narcolepsy and Parkinson's disease
Download PDF File (222 Ko)

Theranexus renforce son équipe de management avec l'arrivée de Thierry Lambert en tant que directeur financier
Download PDF File (210 Ko)

Theranexus announces the nomination of Werner Rein as Chief Medical Officer (CMO)
Download PDF File (93 Ko)

Theranexus annonce la publication d'un article scientifique évaluant le rôle des cellules non neuronales dans le traitement du système nerveux central
Download PDF File (106 Ko)